Two Sigma Investments LP Has $330,000 Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Two Sigma Investments LP lowered its position in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 32.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 320,767 shares of the biotechnology company's stock after selling 150,701 shares during the period. Two Sigma Investments LP owned approximately 0.41% of CytomX Therapeutics worth $330,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. Miller Financial Services LLC purchased a new position in CytomX Therapeutics during the fourth quarter worth $26,000. Algert Global LLC purchased a new stake in shares of CytomX Therapeutics during the 4th quarter valued at $35,000. Aspire Growth Partners LLC acquired a new stake in CytomX Therapeutics during the fourth quarter worth about $42,000. Prudential Financial Inc. increased its position in CytomX Therapeutics by 76.2% during the 4th quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company's stock worth $66,000 after purchasing an additional 27,800 shares in the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in shares of CytomX Therapeutics by 302.2% in the 4th quarter. Cubist Systematic Strategies LLC now owns 98,383 shares of the biotechnology company's stock valued at $101,000 after acquiring an additional 73,923 shares during the period. Hedge funds and other institutional investors own 67.77% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CTMX shares. Wall Street Zen upgraded CytomX Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday, May 13th. Piper Sandler boosted their price target on CytomX Therapeutics from $2.50 to $5.00 and gave the company an "overweight" rating in a report on Thursday, May 15th. HC Wainwright raised CytomX Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 target price for the company in a report on Thursday, May 15th. Finally, Wedbush reiterated an "outperform" rating and issued a $6.00 price objective (up from $5.00) on shares of CytomX Therapeutics in a research report on Monday, May 12th.

CytomX Therapeutics Trading Down 8.0%

NASDAQ:CTMX traded down $0.24 during midday trading on Friday, hitting $2.75. 1,969,342 shares of the stock were exchanged, compared to its average volume of 2,152,854. The company has a market capitalization of $221.71 million, a price-to-earnings ratio of 16.18 and a beta of 2.11. The business has a 50-day moving average price of $1.56 and a two-hundred day moving average price of $1.10. CytomX Therapeutics, Inc. has a one year low of $0.40 and a one year high of $3.10.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.18 by $0.09. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The business had revenue of $50.92 million during the quarter, compared to the consensus estimate of $35.42 million. During the same period in the prior year, the business posted $0.17 earnings per share. Sell-side analysts forecast that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.